Co-Diagnostics (CODX) vs Profusa (PFSA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Profusa is the larger company by market cap ($1.8 million vs $1.4 million), about 1.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CODX | PFSA |
|---|---|---|
| Share price | $0.1295 | $0.3234 |
| Market cap | $1.36M | $1.84M |
| 1-day change | -21.32% | -6.40% |
| P/E ratio (TTM) | — | 0.00 |
| EPS (TTM) | $-21.71 | $6,415.28 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $622.49K | — |
| Revenue growth (YoY) | -84.10% | — |
| Net income (latest FY) | $-46.90M | $-35.82M |
| Gross margin | 64.28% | — |
| Operating margin | -8058.83% | — |
| Net margin | -7533.62% | — |
| 52-week high | $13.54 | $1,515.00 |
| 52-week low | $0.1276 | $0.31 |
| Distance from 52-week high | -99.04% | -99.98% |
| Analyst consensus | none | — |
| Avg. price target upside | +2988.80% | — |
| Average volume | 2.03M | 2.74M |
| Shares outstanding | 10.51M | 5.68M |
| Employees | 115 | — |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Co-Diagnostics
CODX stock →Co-Diagnostics, Inc. operates as a molecular diagnostics company that develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally.
Health Care · Medical/Dental Instruments · 115 employees
About Profusa
PFSA stock →Profusa, Inc., a digital health technology company, develops bioengineered sensors for body to detect and continuously transmit clinical-grade data for personal and medical use in the United States. It offers the Lumee Oxygen Platform to monitor compromised tissue for peripheral artery disease, chronic wounds, and reconstructive surgery.
Health Care · Medical/Dental Instruments
CODX vs PFSA FAQ
Which is bigger, Co-Diagnostics or Profusa?
Profusa (PFSA) is larger, with a market capitalization of $1.84M compared with $1.36M for Co-Diagnostics (CODX).
Are Co-Diagnostics and Profusa in the same industry?
Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.